NCT02963935 · Interventional trial
Effect and Safety of Liraglutide 3.0 mg as an Adjunct to Intensive Behaviour Therapy for Obesity in a Non-specialist Setting
Overall registry status Completed
Phase 3
Conditions Metabolism and Nutrition Disorder, Obesity
Delaware Valley sites
- Novo Nordisk Investigational Site · Philadelphia, PA · Philadelphia County
First posted
Registry updated
Added to the directory